Panacea Index Logo

Command Palette

Search for a command to run...

Potential benefits of mindfulness-based interventions in mild cognitive impairment and Alzheimer's disease: an interdisciplinary perspective.

Behavioural brain research
January 1, 1970
Eddy Larouche et al. (3 authors)
Journal ArticleResearch Support, Non-U.S. Gov'tReviewHuman Study
Study Details

Study Goal

The researchers aimed to evaluate whether mindfulness-based interventions (MBI) could delay or prevent the transition from mild cognitive impairment (MCI) to Alzheimer's disease (AD) by addressing adverse factors like stress, depression, and metabolic syndrome.

Results Summary

The study suggests that MBI may help manage stress, depressive symptoms, and inflammation, potentially slowing MCI/AD progression. Mechanisms include regulation of glucocorticosteroids, inflammation, and serotonin, as well as metabolic syndrome resolution.

Population

Individuals with mild cognitive impairment (MCI) at risk of developing Alzheimer's disease (AD).

Effective Dosage

Not specified

Duration

Not specified

Interactions

None mentioned

Extracted Claims (8)
InterventionDirectionEndpointPopulationDosageImpactClaim #
mindfulness-based interventions (MBI)
decrease
delay, perhaps prevent, the transition from MCI to AD
patients with mild cognitive impairment (MCI)
-
show promise
#1
mindfulness-based interventions (MBI)
decrease
adverse factors
-
-
impacts
#2
mindfulness-based interventions (MBI)
decrease
stress and depression
-
-
mediate
#3
mindfulness-based interventions (MBI)
decrease
the metabolic syndrome
-
-
resolution
#4
mindfulness-based interventions (MBI)
decrease
inflammation and white matter hyperintensities
-
-
reduction
#5
mindfulness-based interventions (MBI)
neutral
insulin and oxidation
-
-
normalization
#6
mindfulness-based interventions (MBI)
neutral
MCI/AD development
-
-
main reach
#7
mindfulness-based interventions (MBI)
decrease
stress, depressive symptoms, and inflammation
-
-
management
#8
Abstract

The present article is based on the premise that the risk of developing Alzheimer's disease (AD) from its prodromal phase (mild cognitive impairment; MCI) is higher when adverse factors (e.g., stress, depression, and metabolic syndrome) are present and accumulate. Such factors augment the likelihood of hippocampal damage central in MCI/AD aetiology, as well as compensatory mechanisms failure triggering a switch toward neurodegeneration. Because of the devastating consequences of AD, there is a need for early interventions that can delay, perhaps prevent, the transition from MCI to AD. We hypothesize that mindfulness-based interventions (MBI) show promise with regard to this goal. The present review discusses the associations between modifiable adverse factors and MCI/AD decline, MBI's impacts on adverse factors, and the mechanisms that could underlie the benefits of MBI. A schematic model is proposed to illustrate the course of neurodegeneration specific to MCI/AD, as well as the possible preventive mechanisms of MBI. Whereas regulation of glucocorticosteroids, inflammation, and serotonin could mediate MBI's effects on stress and depression, resolution of the metabolic syndrome might happen through a reduction of inflammation and white matter hyperintensities, and normalization of insulin and oxidation. The literature reviewed in this paper suggests that the main reach of MBI over MCI/AD development involves the management of stress, depressive symptoms, and inflammation. Future research must focus on achieving deeper understanding of MBI's mechanisms of action in the context of MCI and AD. This necessitates bridging the gap between neuroscientific subfields and a cross-domain integration between basic and clinical knowledge.

Medical Subject Headings (MeSH)
Alzheimer DiseaseCognitive DysfunctionDepressionHumansMetabolic SyndromeMindfulnessModels, BiologicalStress, Psychological
Study Links
Quality Scores
SafetyNot Assessed
Efficacy75/10
Quality80/10
Citation Metrics
Total Citations46
Citations/Year4.6
Relative Citation Ratio2.34
NIH Percentile79%
Research Impact Scores
APT Score0.75
Weight Score1.85
Normalized Score0.66
Related Supplements